Oppenheimer & Co. Inc. Sells 4,137 Shares of Gilead Sciences, Inc. $GILD

Oppenheimer & Co. Inc. decreased its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 1.4% during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 293,320 shares of the biopharmaceutical company’s stock after selling 4,137 shares during the period. Oppenheimer & Co. Inc.’s holdings in Gilead Sciences were worth $32,559,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. GoalVest Advisory LLC grew its holdings in shares of Gilead Sciences by 7,566.7% during the 2nd quarter. GoalVest Advisory LLC now owns 230 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 227 shares during the last quarter. Corundum Trust Company INC bought a new position in Gilead Sciences in the 3rd quarter valued at approximately $26,000. Harbor Asset Planning Inc. acquired a new stake in Gilead Sciences in the second quarter valued at approximately $27,000. Putney Financial Group LLC grew its stake in shares of Gilead Sciences by 53.4% during the second quarter. Putney Financial Group LLC now owns 270 shares of the biopharmaceutical company’s stock worth $30,000 after buying an additional 94 shares during the last quarter. Finally, Howard Hughes Medical Institute acquired a new position in shares of Gilead Sciences during the second quarter worth $30,000. 83.67% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

GILD has been the topic of several recent research reports. Citigroup raised their price objective on Gilead Sciences from $140.00 to $156.00 and gave the company a “buy” rating in a report on Tuesday, January 27th. JPMorgan Chase & Co. lifted their price target on Gilead Sciences from $145.00 to $150.00 and gave the company an “overweight” rating in a research note on Friday, October 31st. BMO Capital Markets boosted their price target on Gilead Sciences from $135.00 to $150.00 and gave the stock an “outperform” rating in a report on Monday, January 26th. Morgan Stanley dropped their price objective on shares of Gilead Sciences from $151.00 to $150.00 and set an “overweight” rating for the company in a report on Tuesday, January 13th. Finally, Wells Fargo & Company lifted their target price on shares of Gilead Sciences from $145.00 to $150.00 and gave the stock an “overweight” rating in a research report on Wednesday, December 10th. One analyst has rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat, Gilead Sciences has an average rating of “Moderate Buy” and a consensus price target of $136.73.

Gilead Sciences Stock Performance

NASDAQ:GILD opened at $152.50 on Monday. The company has a quick ratio of 1.31, a current ratio of 1.45 and a debt-to-equity ratio of 1.03. Gilead Sciences, Inc. has a twelve month low of $93.37 and a twelve month high of $153.13. The company has a fifty day moving average of $127.38 and a 200-day moving average of $121.04. The firm has a market capitalization of $189.20 billion, a P/E ratio of 23.64, a P/E/G ratio of 0.80 and a beta of 0.36.

Insider Activity at Gilead Sciences

In related news, CFO Andrew D. Dickinson sold 3,000 shares of the business’s stock in a transaction dated Thursday, January 15th. The stock was sold at an average price of $124.31, for a total value of $372,930.00. Following the completion of the sale, the chief financial officer directly owned 150,503 shares of the company’s stock, valued at $18,709,027.93. The trade was a 1.95% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Johanna Mercier sold 28,000 shares of the company’s stock in a transaction that occurred on Monday, November 17th. The stock was sold at an average price of $125.86, for a total value of $3,524,080.00. Following the transaction, the insider directly owned 107,193 shares in the company, valued at $13,491,310.98. The trade was a 20.71% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 373,037 shares of company stock worth $50,731,512. 0.27% of the stock is currently owned by insiders.

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.